Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Systematic Financial Management LP

Posted by Geri Gentry on Jul 24th, 2026

Systematic Financial Management LP increased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 3.4% during the 1st quarter, HoldingsChannel.com reports. The fund owned 747,515 shares of the biopharmaceutical company’s stock after purchasing an additional 24,273 shares during the period. Systematic Financial Management LP’s holdings in Catalyst Pharmaceuticals were worth $18,509,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Deerfield Management Company L.P. increased its stake in shares of Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after acquiring an additional 2,095,291 shares during the period. Janus Henderson Group PLC lifted its position in shares of Catalyst Pharmaceuticals by 200.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock valued at $40,124,000 after acquiring an additional 1,147,565 shares during the last quarter. Morgan Stanley boosted its stake in shares of Catalyst Pharmaceuticals by 59.1% during the 4th quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after acquiring an additional 1,089,775 shares in the last quarter. Glenmede Investment Management LP increased its stake in Catalyst Pharmaceuticals by 781.8% in the 3rd quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock worth $13,400,000 after purchasing an additional 603,084 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Catalyst Pharmaceuticals by 30.6% during the 2nd quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock worth $51,335,000 after buying an additional 554,200 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $31.49 on Friday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The business has a 50-day moving average of $31.38 and a 200-day moving average of $27.27. The company has a market capitalization of $3.86 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Oppenheimer lowered shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Stephens set a $32.00 target price on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Finally, Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

View Our Latest Research Report on CPRX

Catalyst Pharmaceuticals Profile

(Free Report)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).